Gambaran Umum
N4 Pharma Plc is a pharmaceutical company based in the United Kingdom, primarily focused on the development and commercialization of novel drug delivery systems. The company specializes in enhancing the performance of existing medications and vaccines through advanced formulation and delivery technologies. A key project for N4 Pharma involves the reformulation of sildenafil, commonly known as Viagra, into a more efficient and faster-acting product. Additionally, the company is engaged in the development of Nuvec®, a unique silica nanoparticle delivery system designed for cancer treatments and vaccine delivery. This technology aims to improve the efficacy and safety profile of therapeutic drugs and vaccines, marking N4 Pharma as a significant player in the innovation of drug delivery solutions within the pharmaceutical industry.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk N4 Pharma Plc per 2024 Dec 31 adalah 0.01 MM.
- Nilai operating income untuk N4 Pharma Plc per 2024 Dec 31 adalah -1.22 MM.
- Nilai net income untuk N4 Pharma Plc per 2024 Dec 31 adalah -1.06 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2024-12-31 | 0.01 | -1.22 | -1.06 |
| 2024-09-30 | 0.01 | -1.20 | -1.07 |
| 2024-06-30 | 0.01 | -1.18 | -1.08 |
| 2024-03-31 | 0.00 | -1.26 | -1.17 |
| 2023-12-31 | 0.00 | -1.34 | -1.27 |
| 2023-09-30 | 0.00 | -1.21 | -1.10 |
| 2023-06-30 | -1.09 | -0.93 | |
| 2023-03-31 | -1.14 | -0.98 | |
| 2022-12-31 | -1.19 | -1.03 | |
| 2022-09-30 | -1.41 | -1.18 | |
| 2022-06-30 | -1.62 | -1.32 | |
| 2022-03-31 | -1.73 | -1.43 | |
| 2021-12-31 | -1.84 | -1.54 | |
| 2021-09-30 | -1.90 | -1.64 | |
| 2021-06-30 | -1.95 | -1.74 | |
| 2021-03-31 | -1.76 | -1.52 | |
| 2020-12-31 | -1.56 | -1.30 | |
| 2020-09-30 | -1.27 | -1.08 | |
| 2020-06-30 | |||
| 2020-03-31 |
Laporan Laba Rugi: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | -0.00 | -0.00 |
| 2024-03-31 | -0.00 | -0.00 |
| 2023-12-31 | -0.01 | -0.01 |
| 2023-09-30 | -0.00 | -0.00 |
| 2023-06-30 | -0.00 | -0.00 |
| 2023-03-31 | -0.00 | -0.00 |
| 2022-12-31 | -0.01 | -0.01 |
| 2022-09-30 | -0.01 | -0.01 |
| 2022-06-30 | -0.01 | -0.01 |
| 2022-03-31 | -0.01 | -0.01 |
| 2021-12-31 | -0.01 | -0.01 |
| 2021-09-30 | -0.01 | -0.01 |
| 2021-06-30 | -0.01 | -0.01 |
| 2021-03-31 | -0.01 | -0.01 |
| 2020-12-31 | -0.01 | -0.01 |
| 2020-09-30 | -0.01 | -0.01 |
| 2020-06-30 | -0.01 | -0.01 |
| 2020-03-31 | -0.01 | -0.01 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk N4 Pharma Plc per 2024 Dec 31 adalah -0.97 MM.
- Nilai kas dari aktivitas pendanaan untuk N4 Pharma Plc per 2024 Dec 31 adalah 0.57 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2024-12-31 | -0.97 | 0.57 | |
| 2024-09-30 | -0.97 | 0.00 | 0.73 |
| 2024-06-30 | -0.97 | 0.00 | 0.89 |
| 2024-03-31 | -1.09 | 0.00 | 0.60 |
| 2023-12-31 | -1.21 | 0.00 | 0.32 |
| 2023-09-30 | -1.23 | 0.00 | 0.64 |
| 2023-06-30 | -1.25 | 0.96 | |
| 2023-03-31 | -1.04 | 0.96 | |
| 2022-12-31 | -0.83 | 0.96 | |
| 2022-09-30 | -0.90 | 0.48 | |
| 2022-06-30 | -0.97 | 0.00 | |
| 2022-03-31 | -1.37 | 0.00 | |
| 2021-12-31 | -1.77 | 0.00 | |
| 2021-09-30 | -1.87 | 1.03 | |
| 2021-06-30 | -1.96 | 2.06 | |
| 2021-03-31 | -1.67 | 3.02 | |
| 2020-12-31 | -1.38 | 3.97 | |
| 2020-09-30 | -1.00 | 2.93 | |
| 2020-06-30 | |||
| 2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 | |||
| 2020-06-30 | |||
| 2020-03-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 | ||
| 2020-06-30 | ||
| 2020-03-31 |
Efektivitas Manajemen
- roa untuk N4 Pharma Plc pada 2024 Dec 31 adalah -0.85.
- roe untuk N4 Pharma Plc pada 2024 Dec 31 adalah -0.89.
- roic untuk N4 Pharma Plc pada 2024 Dec 31 adalah -0.84.
- croic untuk N4 Pharma Plc pada 2024 Dec 31 adalah -0.07.
- ocroic untuk N4 Pharma Plc pada 2024 Dec 31 adalah -0.76.
| Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
| 2024-12-31 | -0.85 | -0.89 | -0.84 | -0.07 | -0.76 |
| 2024-09-30 | -0.84 | -0.90 | -0.84 | -0.07 | -0.76 |
| 2024-06-30 | -0.85 | -0.81 | -1.06 | -0.75 | -1.01 |
| 2024-03-31 | -0.43 | -0.61 | |||
| 2023-12-31 | -0.51 | -0.53 | -0.76 | -0.41 | -0.85 |
| 2023-09-30 | -0.58 | -0.67 | -0.64 | -0.20 | -0.87 |
| 2023-06-30 | -0.64 | -0.67 | -0.64 | -0.20 | -0.87 |
| 2023-03-31 | -0.64 | -0.70 | -0.68 | -0.05 | -0.72 |
| 2022-12-31 | -0.56 | -0.55 | -0.56 | -0.20 | -0.43 |
| 2022-09-30 | -0.56 | -0.55 | -0.56 | -0.20 | -0.43 |
| 2022-06-30 | -0.55 | -0.49 | -0.95 | -0.69 | -0.70 |
| 2022-03-31 | -0.55 | -0.53 | -1.03 | -0.99 | -0.99 |
| 2021-12-31 | -0.45 | -0.42 | -0.73 | -0.83 | -0.73 |
| 2021-09-30 | -0.43 | -0.45 | -0.77 | -0.39 | -0.73 |
| 2021-06-30 | -0.69 | -0.74 | -0.65 | 0.04 | -0.73 |
| 2021-03-31 | -0.61 | -0.65 | -0.57 | 0.50 | -0.62 |
| 2020-12-31 | -1.23 | -1.32 | -0.36 | 0.71 | -0.38 |
| 2020-09-30 | -1.02 | -1.10 | -0.30 | 0.53 | -0.27 |
| 2020-06-30 | -0.60 | -0.65 | -0.36 | 0.54 | -0.26 |
| 2020-03-31 | -0.61 | -0.65 | -0.37 | 0.31 | -0.30 |
Gross Margins
- marjin kotor untuk N4 Pharma Plc pada 2024 Dec 31 adalah -14.22.
- marjin bersih untuk N4 Pharma Plc pada 2024 Dec 31 adalah -184.00.
- marjin operasi untuk N4 Pharma Plc pada 2024 Dec 31 adalah -216.72.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
| Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
| 2024-12-31 | -14.22 | -184.00 | -216.72 |
| 2024-09-30 | -14.22 | -184.00 | -216.72 |
| 2024-06-30 | -44.66 | -649.94 | -683.78 |
| 2024-03-31 | |||
| 2023-12-31 | 1.00 | -1,123.15 | -1,240.61 |
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 | |||
| 2020-06-30 | |||
| 2020-03-31 | 1.00 | -73.92 | -82.01 |
Pengenal dan Deskriptor
| Kunci Indeks Pusat (CIK) |
